Search
R1626
go.drugbank.com/drugs/DB05060ExperimentalR1626 is one of a new class of hepatitis C therapies called polymerase inhibitors.
Elsamitrucin
go.drugbank.com/drugs/DB05129InvestigationalThe cytostatic agent Elsamitrucin is a new fermentation product active in a variety of in vivo tumor models of murine and human origin. (PMID: 8150873)
Sofalcone
go.drugbank.com/drugs/DB05197ExperimentalSofalcone is a mucosal protective agent that has been reported to inhibit growth of Helicobacter pylori. on adherence, production of vacuolating toxin (VT), and induction of interleukin-8 (IL-8) secretion
BTA9881
go.drugbank.com/drugs/DB05226InvestigationalBTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials.
Huperzine B
go.drugbank.com/drugs/DB03348ExperimentalHuperzine B is a novel acetylcholinesterase inhibitor.
TB-402
go.drugbank.com/drugs/DB06050InvestigationalTB-402 is a human antibody binding to Factor VIII, which plays a crucial role in the coagulation of the blood. … It is expected to be developed as a potential treatment to prevent blood clot formation in connection with certain types of heart arrhythmia, such as atrial fibrillation.
R343
go.drugbank.com/drugs/DB06316InvestigationalR343, was investigated in clinical trial NCT01591044 to evaluate its safety and efficacy in patients with mild to moderate asthma.
Porfiromycin
go.drugbank.com/drugs/DB06478InvestigationalPorfiromycin is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called anticancer antibiotics.
Manitimus
go.drugbank.com/drugs/DB06481InvestigationalFK778, a novel compound with multiple mechanisms of action, is efficacious, well tolerated and safe in kidney transplant patients, potentially offering a breakthrough in immunosuppressive therapy.